Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 1.41B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.12M |
| Shares Out | 47.57M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 9 |
| Last Price | $29.54 |
| Previous Close | $30.00 |
| Change ($) | -0.46 |
| Change (%) | -1.53% |
| Day's Open | 30.04 |
| Day's Range | 28.94 - 31.00 |
| Day's Volume | 95,375 |
| 52-Week Range | 25.09 - 40.49 |
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the ...
Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Edgewise Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About EWTX
Edgewise Therapeutics' vision is to improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combi... [Read more...]
| Industry Biotechnology | IPO Date Mar 26, 2021 |
| CEO Kevin Koch, Ph.D. | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol EWTX |